BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways

BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways

Immune checkpoint inhibitors (ICIs) such as the anti-PD-1 antibody Nivolumab, achieve remarkable clinical efficacy in patients with late stage cancers. However, only a small subset of patients benefit from this therapy. Numerous clinical trials are underway testing whether combining ICIs with other...

Full description

Bibliographic Details
Main Authors: Peng Yue, Taylor Harper, Silvia M. Bacot, Monica Chowdhury, Shiowjen Lee, Adovi Akue, Mark A. Kukuruga, Tao Wang, Gerald M. Feldman
Format: Article
Language:English
Published: Taylor & Francis Group 2019-01-01
Series:OncoImmunology
Subjects:
melanoma
nivolumab
braf inhibitor
mek inhibitor
t cell activation
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1512456

Internet

http://dx.doi.org/10.1080/2162402X.2018.1512456

Similar Items